Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
The panelists in this roundtable discussion included: John Allinson, head of biomarker strategy, drug development services at LGC; Martha S. Rook, head of novel therapies, process solutions, MilliporeSigma; Joe Codamo, general manager, Patheon; Brian Hampson, Vice-President, Global Manufacturing Sciences and Technology, PCT, a Caladrius Company; Stephen Gacheru, Executive Director–Biopharmaceutical Product Development, PPD Laboratories; Bruce Stauffer, Executive Director–Immunochemistry Department, PPD Laboratories; and Mark Rogers, VP USA–Life Science, SGS.
Download the
BioPharm International 2016 Outsourcing Resources eBook.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.